Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 16, 2023

BUY
$0.9 - $1.85 $22,500 - $46,250
25,000 New
25,000 $46,000
Q4 2021

Feb 15, 2022

BUY
$7.11 - $9.64 $71,100 - $96,400
10,000 Added 100.0%
20,000 $167,000
Q3 2020

Nov 17, 2020

BUY
$4.58 - $10.95 $45,800 - $109,500
10,000 New
10,000 $82,000

Others Institutions Holding JNCE

About Jounce Therapeutics, Inc.


  • Ticker JNCE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,694,200
  • Description
  • Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...
More about JNCE
Track This Portfolio

Track Colony Group LLC Portfolio

Follow Colony Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Colony Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Colony Group LLC with notifications on news.